Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Figure 2

Administered product, suspension of autologous MSC 3P in 1.5 mL (Bioinova, Ltd., Prague, Czech Republic), was analyzed for the expression of MSC surface markers and surface markers of possible contaminating cells (a) and tested for multipotent differentiation capacity (b). In vitro differentiation into adipocytes ((b) left, scale bar 100 m), osteoblasts ((b) middle, scale bar 100 m), and chondrocytes ((b) right, scale bar 50 m).

(a)

(b)